AccessibilityHelpAbout Us
Drugs Made In America Acquisition Corp. logo

Drugs Made In America Acquisition Corp.(NASDAQ) DMAA

Market Cap$262.19MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)+8%
5 YearN/A
1 Year+5%
1 Month+1%
$10.80
+0.00%
+0.00Today
Drugs Made In America Acquisition Corp. last closing stock price
MetricPriceDate
Last closeUSD 10.802026-09-09
Drugs Made In America Acquisition Corp. stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.37%USD 10.762026-09-02
1 month+0.84%USD 10.712026-08-10
3 month+1.79%USD 10.612026-06-11
Year to date+4.1%USD 10.372025-12-31
1 year+4.85%USD 10.302025-09-09
Since inception+8.43%USD 9.962025-02-25

Drugs Made In America Acquisition Corp. Financials at a Glance

Market Cap

$262.19MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$6.09M

EPS (TTM)

$0.19

P/E Ratio

58.06

Dividend

$0.00

Beta (Volatility)

-0.11 (Low)

Price

$10.80

Volume

34,843

Open

$10.80

Previous Close

$10.80

Daily Range

$10.79 - $10.80

52-Week Range

$10.23 - $10.80

Estimated Earnings Date

May 20, 2025

DMAA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. helps private businesses go public. It searches for pharmaceutical firms to merge with and grow. This provides a path for businesses to reach the Nasdaq.

Searching for a Perfect Match

  • Acquisition Platform: Finding and merging with private businesses to create a new public entity.
  • Capital Trust: Managing investor funds held in a secure account until a deal closes.
  • Sector Targeting: Focusing on businesses within the pharmaceutical industry.

Moving Toward a Deal

  • Finished an initial public offering on Jan. 29, 2025, raising $200 million.
  • Signed a merger agreement with PAGC on April 29, 2026, to create a combined operating business.
  • Secured $500,000 in financing from BV Advisory Partners, LLC in March 2026.
  • Extended the deadline to finish its business combination until April 2027.

Industry Focus and Funding

Drugs Made In America targets the pharmaceutical sector to encourage domestic manufacturing. The company uses a trust account to keep investor funds secure during its search for a partner.

The Financial Scorecard

  • Net income reached $3.7 million for the six-month period ended June 30, 2026.
  • Interest earned on the trust account was $4 million for the six-month period ended June 30, 2026.
  • Market capitalization was $214 million in the second quarter of 2026, down 37.4% year over year.
  • Share redemptions totaled $99.3 million in April 2026.

Bottom Line

Drugs Made In America has moved from a shell company to having a signed merger deal. Its future depends on closing the PAGC transaction and managing its remaining cash reserves.

AI Generated • Aug 15, 2026

Industry

Capital Markets

Sector

Financials

Employees

2

CEO

Roger Emile Bendelac, MBA

Website

www.dmaacorp.com

Headquarters

New York, NY 10170, US

DMAA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

2.92%

Return on Capital

-1.21%

Return on Assets

4.15%

Earnings Yield

1.72%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$262.19MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

24.28M

Volume

34.84K

Avg. Volume

32.95K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$2.63M

EBITDA

-$2.63M

Operating Cash Flow

-$323.13K

Capital Expenditure

-$7.00

Free Cash Flow

-$323.13K

Cash & ST Invst.

$20.28K

Total Debt

$950.00K

Drugs Made In America Acquisition Corp. Performance Analysis

Drugs Made In America Acquisition Corp. annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Drugs Made In America Acquisition Corp. sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Drugs Made In America Acquisition Corp. annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD -0.01N/A
20252025-12-31USD 0.18N/A
Drugs Made In America Acquisition Corp. sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-302.5%
Q42025-12-31-91.0%
Q12026-03-31852.4%
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$262.19MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$131.10M

N/A

Employees

2

N/A

Net Income

$1.73M

-24.5%

EBITDA

-$136.93K

-3.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$20.28K

+2367.2%

Total Debt

$950.00K

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$950.00K

N/A

Return on Assets

4.15%

N/A

Return on Invested Capital

-1.83%

N/A

Free Cash Flow

-$244.61K

+18.6%

Operating Cash Flow

-$244.61K

+18.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RTACRenatus Tactical Acquisition Corp I Class A Ordinary Shares
$10.46+0.05%
LOKVLive Oak Acquisition Corp. V Class A Ordinary Shares
$11.52+0.00%
SIMASIM Acquisition Corp. I
$10.98-0.45%
OYSEOyster Enterprises II Acquisition Corp
$10.38+0.02%

Trending Stocks

Symbol / CompanyPricePrice Chg
TNONTenon Medical
$5.30+1.17%
SPCXSpace Exploration Technologies
$148.18+0.00%
NVDANvidia
$218.36-0.02%
INTCIntel
$100.32-0.06%

Questions About DMAA

What is the current price of Drugs Made In America Acquisition Corp.?

Drugs Made In America Acquisition Corp. is trading at $10.80 per share.

What is the 52-week range for Drugs Made In America Acquisition Corp.?

Over the past 52 weeks, Drugs Made In America Acquisition Corp. has traded between $10.23 and $10.80.

How much debt does Drugs Made In America Acquisition Corp. have?

As of the most recent reporting period, Drugs Made In America Acquisition Corp. reported total debt of $950.00K.

How much cash does Drugs Made In America Acquisition Corp. have on hand?

Drugs Made In America Acquisition Corp. reported $20.28K in cash and cash equivalents in its most recent financial results.

What is Drugs Made In America Acquisition Corp.’s dividend yield?

Drugs Made In America Acquisition Corp. does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services